Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 51Neoplasm Metastasis 19Skin Neoplasms 15Carcinoma, Renal Cell 13Leukemia, Myeloid, Acute 12Kidney Neoplasms 11Leukemia 9Neoplasms 7Uterine Cervical Neoplasms 5Lymphoma 5Congenital Abnormalities 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neuroblastoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Carcinoma, Non-Small-Cell Lung 4Vaginal Neoplasms 2Penile Neoplasms 2Papillomavirus Infections 2Oropharyngeal Neoplasms 2Melanoma, Experimental 2Lymphoma, Mantle-Cell 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Brain Neoplasms 2

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × aldesleukin × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡